Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mirikizumab + LY4395089
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
mirikizumab + LY4395089 is an investigational combination therapy being developed by Eli Lilly and Company for the treatment of moderately to severely active Crohn's disease. The combination consists of mirikizumab (LY3074828), a humanized IgG4 monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23), and LY4395089, an oral small-molecule farnesoid X receptor (FXR) agonist. By combining the systemic anti-inflammatory effects of IL-23 inhibition with the localized gut-protective and anti-inflammatory actions of FXR activation, this regimen aims to enhance mucosal healing and clinical remission rates. The combination is currently being evaluated in a Phase 2 clinical trial (NCT07483099) where patients receive intravenous mirikizumab co-administered with oral LY4395089, followed by subcutaneous mirikizumab maintenance therapy.
- Other names
- LY3074828 + LY4395089LY4395089 + LY3074828LY4395089 + mirikizumabLY4395089 and mirikizumabLY-4395089 and mirikizumabLY 4395089 and mirikizumabmirikizumab and LY4395089
02
Targets
FXR (Farnesoid x-activated receptor)IL23A (Interleukin-23 p19 Subunit)
Beyond the preview
Go deeper on mirikizumab + LY4395089.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mirikizumab + LY4395089.